Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Gynecol Oncol. 2023 May 26;174:262–272. doi: 10.1016/j.ygyno.2023.05.059

Figure 1. Patient selection and molecular classification of endometrial cancers integrating clinical tumor-normal sequencing and immunohistochemistry data.

Figure 1.

A. CONSORT diagram summarizing the endometrial cancer patients included in this study. B. Method employed for classification of endometrial cancers into the molecular subtypes using clinical MSK-IMPACT sequencing results and immunohistochemistry. C. Distribution of histologic subtypes and molecular subtypes for 1,834 endometrial cancers subjected to clinical sequencing. CN-H, copy number-high; CN-L, copy number-low; G1, grade 1; G2, grade 2; G3, grade 3; MSI-H, microsatellite instability-high; NOS, not otherwise specified.